Shares of Editas Medicine Inc. (NASDAQ:EDIT) traded down 5.1% during mid-day trading on Wednesday . The company traded as low as $16.74 and last traded at $16.81, with a volume of 171,123 shares changing hands. The stock had previously closed at $17.71.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Wednesday, June 1st. Jefferies Group assumed coverage on shares of Editas Medicine in a report on Thursday, June 2nd. They set a “hold” rating and a $35.00 target price on the stock. Cowen and Company restated a “buy” rating on shares of Editas Medicine in a report on Monday, May 16th. Finally, Vetr upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 target price on the stock in a report on Monday, May 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $33.50.

The company’s market capitalization is $577.79 million. The company has a 50-day moving average price of $22.38 and a 200-day moving average price of $29.23.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.54). Equities analysts predict that Editas Medicine Inc. will post ($2.59) EPS for the current year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.